The Consumer Reports ratings are based on data hospitals reported to the CDC between October 2014 and September 2015. The data is released periodically over the year. Consumer Reports alsoreleased C.
By Dennis Thompson HealthDay ReporterTHURSDAY, April 9, 2026 (HealthDay News) — Prompt treatment with a fecal transplant can ...
Researchers from the University of Virginia in Charlottesville have discovered a type of gut bacteria that could prove effective where other types of helpful bacteria have failed in the fight against ...
C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...
Verywell Health on MSN
What to eat when you have C diff (Clostridioides difficile)
Medically reviewed by Lindsey Waldman, MD, RD Key Takeaways Eat foods with probiotics like yogurt and kefir to help replenish ...
Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...
There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...
A group of frontline hospital workers who often go unseen in day-to-day patient care was recognized Friday at University ...
Fecal microbiota transplantation has become one of the most effective treatments for recurrent Clostridioides difficile infections, but its long-term role in gastroenterology may hinge on moving ...
SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SABS) (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces ...
The risk of getting a deadly, treatment-resistant infection in a hospital or nursing home is dropping for the first time in decades, thanks to new guidelines on antibiotic use and stricter cleaning ...
After reporting non-statistically significant results in it a phase-II study, Cambridge, Mass.-based Seres Therapeutics is launching a revised phase-II study for its SER-109 Clostridium Difficile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results